Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 Read more
Eisai, Biogen Alzheimer’s drug Leqembi would cost US Medicare up to $5 billion a year, study finds By Reuters Read more